AQST logo

Aquestive Therapeutics, Inc. (AQST) EBITDA

Annual EBITDA:

-$26.62M-$27.80M(-2351.78%)
December 31, 2024

Summary

  • As of today, AQST annual EBITDA is -$26.62 million, with the most recent change of -$27.80 million (-2351.78%) on December 31, 2024.
  • During the last 3 years, AQST annual EBITDA has risen by +$18.50 million (+41.00%).
  • AQST annual EBITDA is now -1137.66% below its all-time high of $2.56 million, reached on December 31, 2017.

Performance

AQST EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAQSTincome statement metrics

Quarterly EBITDA:

-$11.34M-$112.00K(-1.00%)
September 30, 2025

Summary

  • As of today, AQST quarterly EBITDA is -$11.34 million, with the most recent change of -$112.00 thousand (-1.00%) on September 30, 2025.
  • Over the past year, AQST quarterly EBITDA has dropped by -$3.21 million (-39.47%).
  • AQST quarterly EBITDA is now -199.57% below its all-time high of $11.39 million, reached on September 30, 2017.

Performance

AQST Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAQSTincome statement metrics

TTM EBITDA:

-$55.23M-$3.21M(-6.17%)
September 30, 2025

Summary

  • As of today, AQST TTM EBITDA is -$55.23 million, with the most recent change of -$3.21 million (-6.17%) on September 30, 2025.
  • Over the past year, AQST TTM EBITDA has dropped by -$35.16 million (-175.24%).
  • AQST TTM EBITDA is now -521.64% below its all-time high of $13.10 million, reached on September 30, 2017.

Performance

AQST TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAQSTincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

AQST EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-2351.8%-39.5%-175.2%
3Y3 Years+41.0%-37.3%-37.0%
5Y5 Years+50.7%+13.1%-62.1%

AQST EBITDA Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-2351.8%+41.0%-4461.5%+41.0%-301.2%at low
5Y5-Year-2351.8%+50.7%-4461.5%+41.0%-301.2%at low
All-TimeAll-Time-1137.7%+50.7%-199.6%+64.5%-521.6%+14.0%

AQST EBITDA History

DateAnnualQuarterlyTTM
Sep 2025
-
-$11.34M(-1.0%)
-$55.23M(-6.2%)
Jun 2025
-
-$11.23M(+41.6%)
-$52.02M(-28.3%)
Mar 2025
-
-$19.23M(-43.1%)
-$40.53M(-34.9%)
Dec 2024
-$26.62M(-2351.8%)
-$13.43M(-65.2%)
-$30.05M(-49.8%)
Sep 2024
-
-$8.13M(-3227.3%)
-$20.07M(-42.8%)
Jun 2024
-
$260.00K(+103.0%)
-$14.05M(+22.9%)
Mar 2024
-
-$8.75M(-154.1%)
-$18.23M(-32.5%)
Dec 2023
$1.18M(+103.0%)
-$3.44M(-62.5%)
-$13.76M(+33.3%)
Sep 2023
-
-$2.12M(+45.9%)
-$20.64M(+22.9%)
Jun 2023
-
-$3.92M(+8.4%)
-$26.77M(+23.4%)
Mar 2023
-
-$4.28M(+58.5%)
-$34.95M(+11.9%)
Dec 2022
-$39.58M(+12.3%)
-$10.32M(-24.9%)
-$39.68M(+1.5%)
Sep 2022
-
-$8.26M(+31.7%)
-$40.30M(-2.6%)
Jun 2022
-
-$12.10M(-34.2%)
-$39.27M(-19.2%)
Mar 2022
-
-$9.01M(+17.6%)
-$32.96M(-3.9%)
Dec 2021
-$45.11M
-$10.94M(-51.3%)
-$31.71M(+9.8%)
Sep 2021
-
-$7.23M(-25.2%)
-$35.15M(+14.2%)
DateAnnualQuarterlyTTM
Jun 2021
-
-$5.78M(+25.6%)
-$40.97M(-20.2%)
Mar 2021
-
-$7.77M(+45.9%)
-$34.08M(+13.2%)
Dec 2020
-$39.32M(+27.2%)
-$14.37M(-10.1%)
-$39.29M(-15.3%)
Sep 2020
-
-$13.05M(-1279.2%)
-$34.06M(-8.9%)
Jun 2020
-
$1.11M(+108.5%)
-$31.27M(+37.8%)
Mar 2020
-
-$12.97M(-41.9%)
-$50.30M(-1.4%)
Dec 2019
-$54.02M(-7.1%)
-$9.14M(+10.9%)
-$49.62M(+4.7%)
Sep 2019
-
-$10.26M(+42.8%)
-$52.07M(-3.6%)
Jun 2019
-
-$17.93M(-45.9%)
-$50.27M(+21.8%)
Mar 2019
-
-$12.29M(-6.1%)
-$64.25M(-40.6%)
Dec 2018
-$50.43M(-2066.0%)
-$11.59M(-37.0%)
-$45.70M(-13.1%)
Sep 2018
-
-$8.46M(+73.5%)
-$40.40M(-96.6%)
Jun 2018
-
-$31.91M(-609.9%)
-$20.55M(-280.9%)
Mar 2018
-
$6.26M(+199.5%)
$11.36M(+66.8%)
Dec 2017
$2.56M(+493.8%)
-$6.29M(-155.2%)
$6.81M(-48.0%)
Sep 2017
-
$11.39M(+566.4%)
$13.10M(+666.4%)
Mar 2017
-
$1.71M
$1.71M
Dec 2016
$432.00K
-
-

FAQ

  • What is Aquestive Therapeutics, Inc. annual EBITDA?
  • What is the all-time high annual EBITDA for Aquestive Therapeutics, Inc.?
  • What is Aquestive Therapeutics, Inc. annual EBITDA year-on-year change?
  • What is Aquestive Therapeutics, Inc. quarterly EBITDA?
  • What is the all-time high quarterly EBITDA for Aquestive Therapeutics, Inc.?
  • What is Aquestive Therapeutics, Inc. quarterly EBITDA year-on-year change?
  • What is Aquestive Therapeutics, Inc. TTM EBITDA?
  • What is the all-time high TTM EBITDA for Aquestive Therapeutics, Inc.?
  • What is Aquestive Therapeutics, Inc. TTM EBITDA year-on-year change?

What is Aquestive Therapeutics, Inc. annual EBITDA?

The current annual EBITDA of AQST is -$26.62M

What is the all-time high annual EBITDA for Aquestive Therapeutics, Inc.?

Aquestive Therapeutics, Inc. all-time high annual EBITDA is $2.56M

What is Aquestive Therapeutics, Inc. annual EBITDA year-on-year change?

Over the past year, AQST annual EBITDA has changed by -$27.80M (-2351.78%)

What is Aquestive Therapeutics, Inc. quarterly EBITDA?

The current quarterly EBITDA of AQST is -$11.34M

What is the all-time high quarterly EBITDA for Aquestive Therapeutics, Inc.?

Aquestive Therapeutics, Inc. all-time high quarterly EBITDA is $11.39M

What is Aquestive Therapeutics, Inc. quarterly EBITDA year-on-year change?

Over the past year, AQST quarterly EBITDA has changed by -$3.21M (-39.47%)

What is Aquestive Therapeutics, Inc. TTM EBITDA?

The current TTM EBITDA of AQST is -$55.23M

What is the all-time high TTM EBITDA for Aquestive Therapeutics, Inc.?

Aquestive Therapeutics, Inc. all-time high TTM EBITDA is $13.10M

What is Aquestive Therapeutics, Inc. TTM EBITDA year-on-year change?

Over the past year, AQST TTM EBITDA has changed by -$35.16M (-175.24%)
On this page